169815-81-0

Basic information

• Product Name: Furo[2,3-b]pyridine-5-methanol (9CI)
• Synonyms: Furo[2,3-b]pyridine-5-methanol (9CI);furo[2,3-b]pyridin-5-ylmethanol
• CAS NO: 169815-81-0
• Molecular Formula: C8H7NO2
• Molecular Weight: 149.14668
• Product Categories: PYRIDINE
• Mol File: 169815-81-0.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 284.1±25.0 °C(Predicted)
• Appearance: /
• Density: 1.315±0.06 g/cm3(Predicted)
• PKA: 13.56±0.10(Predicted)
• CAS DataBase Reference: Furo[2,3-b]pyridine-5-methanol (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Furo[2,3-b]pyridine-5-methanol (9CI)(169815-81-0)
• EPA Substance Registry System: Furo[2,3-b]pyridine-5-methanol (9CI)(169815-81-0)

Safety Data

• Hazardous Substances Data: 169815-81-0(Hazardous Substances Data)

Upstream product

• 122535-07-3 furo[2,3-b]pyridine-2,5-dicarboxylic acid 
• 6562-80-7 diethyl furo<2,3-b>pyridine-2,5-dicarbaxylate 
• 122534-94-5 furo[2,3-b]pyridine-5-carboxylic acid 
• 160729-79-3 ethyl 6-oxo-5-((trimethylsilyl)ethynyl)-1,6-dihydropyridine-3-carboxylate 
• 160729-80-6 ethyl 1,6-dihydro-5-iodo-6-oxo-3-pyridinecarboxylate 
• 18617-50-0 1-ethyl-2-pyridone-5-carboxylic acid 
• 5006-66-6 6-hydroxynicotinic acid 
• 170959-84-9 (((5-(methoxycarbonyl)-2-furanyl)amino)methylene)propanedioic acid diethyl ester 
• 170959-85-0 4-hydroxyfurol<2,3-b>pyridine-2,5-dicarboxylic acid 5-ethyl 2-methyl ester 
• 124031-00-1 4-chlorofuro<2,3-b>pyridine-2,5-dicarboxylicacid 5-ethyl 2-methyl ester 
• 170959-86-1 furo<2,3-b>pyridine-2,5-dicarboxylic acid 5-ethyl ester 
• 160729-90-8 ethyl furo<2,3-b>pyridyne-5-carboxylate 
• 169815-80-9 methyl furo[2,3-b]pyridine-5-carboxylate 

Downstream Products

• 201470-89-5 5-formylfuro<2,3-b>pyridine 

Relevant articles and documents

A practical synthesis of the 5-chloromethyl-furo[2,3-b]pyridine pharmacophore

Synthesis of the furopyridine 2 was accomplished in 52% overall yield from 6-hydroxynicotinic acid (3). The synthesis is highlighted by a Heck coupling of 5 with ethylene followed by an NCS mediated oxidative cyclization and elimination sequence.

BRIDGED SIX-MEMBERED RING COMPOUNDS

The invention relates to compounds of formula (I), wherein R1, R2, R1a, R2a, R3, R4, A, B, X, W and n are as defined in the description, and pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium channel blockers.

HIV protease inhibitors useful for the treatment of AIDS

Compounds of formula STR1 are HIV protease inhibitors. These compounds are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.